Winston-Salem regenerative medicine company ProKidney reports Q4 loss as R&D, personnel costs increase

ProKidney, which went public in July 2022, is advancing towards two Phase 3 trials with almost $500 million in cash after its merger with Social Capital Suvretta Holdings.